KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Assets (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Current Assets data on record, last reported at $2.5 billion in Q3 2025.

  • For Q3 2025, Current Assets fell 7.18% year-over-year to $2.5 billion; the TTM value through Sep 2025 reached $2.5 billion, down 7.18%, while the annual FY2024 figure was $2.6 billion, 0.82% down from the prior year.
  • Current Assets reached $2.5 billion in Q3 2025 per IONS's latest filing, down from $2.6 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.7 billion in Q3 2024 and bottomed at $2.0 billion in Q1 2021.
  • Average Current Assets over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2024.
  • Peak YoY movement for Current Assets: fell 22.23% in 2021, then grew 20.1% in 2023.
  • A 5-year view of Current Assets shows it stood at $2.3 billion in 2021, then dropped by 6.07% to $2.2 billion in 2022, then rose by 19.94% to $2.6 billion in 2023, then fell by 0.82% to $2.6 billion in 2024, then dropped by 3.87% to $2.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $2.5 billion in Q3 2025, $2.6 billion in Q2 2025, and $2.4 billion in Q1 2025.